Nebivolol Viatris Sante (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivolol Viatris Sante, is a beta‑blocker presented as an oral dosage form for oral use. It is indicated for the management of hypertension and for treatment of heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Nebivolol Viatris Sante as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to strict quality standards and regulatory requirements.

Nebivolol is a selective β1‑adrenergic blocker used in cardiovascular disease management.

Hypertension: lowers systolic and diastolic blood pressure, reducing cardiovascular risk. Heart failure (reduced ejection fraction): improves ventricular function and decreases hospitalization rates. Left ventricular dysfunction: supports cardiac remodeling and enhances exercise tolerance.

Nebivolol may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Fatigue or tiredness - Dizziness or light‑headedness - Headache - Bradycardia (slow heart rate) - Nausea - Cough

Serious or Rare Side Effects: - Severe bradycardia or heart block - Marked hypotension - Bronchospasm, especially in patients with asthma or COPD - Allergic reactions such as rash or angioedema - Hepatic dysfunction or elevated liver enzymes - Cardiogenic shock in susceptible individuals

Before prescribing Nebivolol, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Monitor blood pressure: ensure adequate control and avoid excessive hypotension. - Assess cardiac function: evaluate baseline heart rate and ejection fraction. - Use caution in asthma or COPD: β‑blockade may precipitate bronchospasm. - Review concomitant beta‑blocker therapy: avoid additive effects. - Adjust dose in renal impairment: consider reduced clearance. - Store at room temperature: keep in the original pack, protect from moisture.

Nebivolol can interact with several drug classes, requiring careful assessment.

Major Interactions (Avoid): - Other beta‑blockers: additive negative chronotropic effects. - Calcium‑channel blockers verapamil or diltiazem: may increase bradycardia risk. - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): raise nebivolol plasma concentrations.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate hypotensive response. - NSAIDs: can attenuate antihypertensive efficacy. - Antidiabetic agents: blood‑glucose control may be altered, requiring dose adjustment.